Item Type | Name |
Concept
|
Adjuvants, Immunologic
|
Concept
|
Immunoglobulin Fab Fragments
|
Concept
|
Immunosuppressive Agents
|
Concept
|
Enzyme Inhibitors
|
Concept
|
Immunologic Factors
|
Concept
|
Dose-Response Relationship, Drug
|
Concept
|
Enzyme-Linked Immunosorbent Assay
|
Concept
|
Immunity, Cellular
|
Concept
|
Immunohistochemistry
|
Concept
|
Phosphodiesterase Inhibitors
|
Concept
|
Immunoglobulin G
|
Concept
|
Immunoenzyme Techniques
|
Concept
|
Lipoxygenase Inhibitors
|
Concept
|
Cyclooxygenase 2 Inhibitors
|
Concept
|
Immunoconjugates
|
Concept
|
Structure-Activity Relationship
|
Concept
|
Immunoprecipitation
|
Concept
|
Immunoblotting
|
Concept
|
Adaptive Immunity
|
Concept
|
Immunity
|
Concept
|
Immunity, Innate
|
Concept
|
Researcher-Subject Relations
|
Concept
|
Proton Pump Inhibitors
|
Academic Article
|
New therapeutic approaches.
|
Academic Article
|
Protection from primary sclerosing cholangitis: smoke trails of just coattails?
|
Academic Article
|
Cyclosporin for severe ulcerative colitis: a user's guide.
|
Academic Article
|
Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group.
|
Academic Article
|
No butts about it: put the fire out by lighting up.
|
Academic Article
|
A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin.
|
Academic Article
|
Medical management of perianal Crohn's disease.
|
Academic Article
|
Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591.
|
Academic Article
|
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
|
Academic Article
|
Medical therapy for inflammatory bowel disease.
|
Academic Article
|
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.
|
Academic Article
|
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
|
Academic Article
|
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.
|
Academic Article
|
Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group.
|
Academic Article
|
Evolving treatment strategies for inflammatory bowel disease.
|
Academic Article
|
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
|
Academic Article
|
Infliximab for the treatment of fistulas in patients with Crohn's disease.
|
Academic Article
|
Comparative tolerability of treatments for inflammatory bowel disease.
|
Academic Article
|
Efficacy of parenteral methotrexate in refractory Crohn's disease.
|
Academic Article
|
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
|
Academic Article
|
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
|
Academic Article
|
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.
|
Academic Article
|
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
|
Academic Article
|
Update on medical management of inflammatory bowel disease: ulcerative colitis.
|
Academic Article
|
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
|
Academic Article
|
Biologics in peri-operative management of Crohn's disease.
|
Academic Article
|
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
|
Academic Article
|
Immunogenicity of infliximab in Crohn's disease.
|
Academic Article
|
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial.
|
Academic Article
|
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.
|
Academic Article
|
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
|
Academic Article
|
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
|
Academic Article
|
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.
|
Academic Article
|
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
|
Academic Article
|
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.
|
Academic Article
|
Treatment of inflammatory bowel disease: safety and tolerability issues.
|
Academic Article
|
Review article: the long-term management of ulcerative colitis.
|
Academic Article
|
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
|
Academic Article
|
COLAL-PRED Alizyme.
|
Academic Article
|
The state of the art in the management of inflammatory bowel disease.
|
Academic Article
|
Unemployment and disability in patients with moderately to severely active Crohn's disease.
|
Academic Article
|
Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
|
Academic Article
|
Safety first: messages from Digestive Disease Week 2006.
|
Academic Article
|
Natalizumab induction and maintenance therapy for Crohn's disease.
|
Academic Article
|
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
|
Academic Article
|
Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down".
|
Academic Article
|
A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis.
|
Academic Article
|
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
|
Academic Article
|
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.
|
Academic Article
|
Immunosuppressive therapy in the formation of antibodies to infliximab in Crohn's disease.
|
Academic Article
|
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
|
Academic Article
|
Refining the role of TNF antagonists for Crohn's disease. Introduction.
|
Academic Article
|
Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort.
|
Academic Article
|
Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease.
|
Academic Article
|
Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
|
Academic Article
|
Controversies with aminosalicylates in inflammatory bowel disease.
|
Academic Article
|
Selecting appropriate anti-TNF agents in inflammatory bowel disease.
|
Academic Article
|
Optimizing conventional therapies for inflammatory bowel disease.
|
Academic Article
|
Devolving therapeutic pyramids.
|
Academic Article
|
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
|
Academic Article
|
Conflicts of interest.
|
Academic Article
|
General principles and pharmacology of biologics in inflammatory bowel disease.
|
Academic Article
|
Addicted to acid suppression.
|
Academic Article
|
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
|
Academic Article
|
Medical management of Crohn's disease: treatment algorithms 2009.
|
Academic Article
|
African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity.
|
Academic Article
|
Inflammatory bowel disease.
|
Academic Article
|
Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
|
Academic Article
|
Where do our priorities lie?
|
Academic Article
|
Maintenance therapy with certolizumab pegol for Crohn's disease.
|
Academic Article
|
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
|
Academic Article
|
An evidence-based systematic review on medical therapies for inflammatory bowel disease.
|
Academic Article
|
Tumor-associated glycoprotein (TAG-72) expression in ulcerative colitis.
|
Academic Article
|
Calcineurin inhibition in severe ulcerative colitis: lost in translation?
|
Academic Article
|
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.
|
Academic Article
|
Treatment of inflammatory bowel disease: a review of medical therapy.
|
Academic Article
|
Disease modification in inflammatory bowel disease.
|
Academic Article
|
Update on the management of ulcerative colitis.
|
Academic Article
|
Abatacept for Crohn's disease and ulcerative colitis.
|
Academic Article
|
Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction.
|
Academic Article
|
Management of inflammatory bowel disease: past, present and future.
|
Academic Article
|
Treatment of Crohn's disease: the "long" of it.
|
Academic Article
|
Disseminated Trichosporon beigelii (cutaneum).
|
Academic Article
|
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study.
|
Academic Article
|
The management of ulcerative colitis.
|
Academic Article
|
Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study.
|
Academic Article
|
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.
|
Academic Article
|
Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study.
|
Academic Article
|
What to take from TREAT?
|
Academic Article
|
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
|
Academic Article
|
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
|
Academic Article
|
Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.
|
Academic Article
|
"Hit me with your best shot... Fire away!".
|
Academic Article
|
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
|
Academic Article
|
Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease.
|
Academic Article
|
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
|
Academic Article
|
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
|
Academic Article
|
Crohn's disease. The problem and its management.
|
Academic Article
|
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
|
Academic Article
|
Inflammatory bowel disease.
|
Academic Article
|
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
|
Academic Article
|
Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid.
|
Academic Article
|
Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin.
|
Academic Article
|
Mesalamine capsules enhance the quality of life for patients with ulcerative colitis.
|
Academic Article
|
Medical therapy to reduce postoperative Crohn's disease recurrence.
|
Academic Article
|
Medical therapy for ulcerative colitis 2004.
|
Academic Article
|
Inflammatory bowel disease revisited: newer drugs.
|
Academic Article
|
Parallel universes.
|
Academic Article
|
Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease.
|
Academic Article
|
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.
|
Academic Article
|
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
|
Academic Article
|
Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease.
|
Academic Article
|
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.
|
Academic Article
|
Medical therapy of ulcerative colitis.
|
Academic Article
|
Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions.
|
Academic Article
|
Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
|
Academic Article
|
Reassessing the risks and benefits of thiopurines in Crohn's disease.
|
Academic Article
|
Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy.
|
Academic Article
|
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
|
Academic Article
|
Diphenhydramine provides relief of cyclophosphamide-related symptoms.
|
Academic Article
|
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease.
|
Academic Article
|
Heading back to the trough (levels of biologics in IBD).
|
Academic Article
|
In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease.
|
Academic Article
|
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease.
|
Academic Article
|
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
|
Academic Article
|
Vedolizumab as induction and maintenance therapy for Crohn's disease.
|
Academic Article
|
Still in pursuit.
|
Academic Article
|
Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.
|
Academic Article
|
Comparing guidelines for the treatment of inflammatory bowel disease.
|
Academic Article
|
Comment on 'anti-adhesion therapies and the rule of 3 for rare events'.
|
Academic Article
|
Treat to target: a proposed new paradigm for the management of Crohn's disease.
|
Academic Article
|
Reply: To PMID 25311382.
|
Academic Article
|
Hyperacute Methotrexate Pneumonitis in a Patient With Crohn's Disease.
|
Academic Article
|
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
|
Academic Article
|
The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal Exposure.
|
Academic Article
|
Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.
|
Academic Article
|
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
|
Academic Article
|
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
|
Academic Article
|
Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease?
|
Academic Article
|
Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy.
|
Academic Article
|
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
|
Academic Article
|
Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).
|
Academic Article
|
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
|
Academic Article
|
Checkpoint Inhibitor-Induced Colitis.
|
Academic Article
|
Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis.
|
Academic Article
|
Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
|
Academic Article
|
Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes.
|
Academic Article
|
Neutrophils Alter DNA Repair Landscape to Impact Survival and Shape Distinct Therapeutic Phenotypes of Colorectal Cancer.
|
Academic Article
|
Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes.
|
Academic Article
|
Patient Perspectives on Medical Trauma Related to Inflammatory Bowel Disease.
|
Academic Article
|
Review article: drug-induced small bowel injury.
|
Academic Article
|
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
|
Academic Article
|
Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).
|
Academic Article
|
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
|
Academic Article
|
Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel.
|
Academic Article
|
Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis.
|
Academic Article
|
Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease.
|
Academic Article
|
Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease.
|
Concept
|
Poly(ADP-ribose) Polymerase Inhibitors
|
Concept
|
Antineoplastic Agents, Immunological
|
Concept
|
Janus Kinase Inhibitors
|
Concept
|
Drug-Related Side Effects and Adverse Reactions
|
Concept
|
Calcineurin Inhibitors
|
Grant
|
Multi-site Trial of Azathioprine Dosing in Crohn Disease
|
Grant
|
Multi-site Trial of Azathioprine Dosing in Crohn Disease
|
Academic Article
|
The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease.
|
Academic Article
|
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases.
|